Page 3 - சாமுவேல் காந்தி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

National News Answers to controversial Alzheimer s drug may miss 2030 target WASHINGTON (AP) When a controversial Alzheimer s drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take to find out if it really works nine years. by Associated Press Jul. 1 2021 @ 11:05pm FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. Drugmaker Biogen has until 2030 to complete a study confirming whether the new drug truly slows the brain-destroying disease. That s under the terms of the Food and Drug Administration s conditional approval of the drug, a decision that has been praised by patients as overdue and condemned by the agency s own outside experts. (Biogen via AP, File)

United statesJoseph rossMaria carrilloSamuel gandyDonna wilcockJoshua wallachYale school of public healthAlzheimer associationDrug administrationUniversity of kentuckyNew yorkMount sinaiSarepta therapeuticsஒன்றுபட்டது மாநிலங்களில்ஜோசப் ரோஸ்மரியா கரில்லோ